Malin Corporation

CG Oncology is a clinical-stage biopharmaceutical company dedicated to developing innovative immunotherapies for cancer treatment, particularly focusing on bladder cancer. The company specializes in oncolytic immunotherapies, with its lead candidate, cretostimogene grenadenorepvec, designed as a targeted, intravesical immunotherapy. Currently, CG Oncology is conducting multiple clinical trials, including two phase three trials aimed at high-risk patients with non-muscle invasive bladder cancer (NMIBC) who are unresponsive to BCG therapy, as well as an additional phase two study in combination with a checkpoint inhibitor. The company aims to provide effective bladder-sparing treatment options for patients while advancing the development of its proprietary therapies.

CG Oncology is a clinical-stage biopharmaceutical company dedicated to developing innovative immunotherapies for cancer treatment, particularly focusing on bladder cancer. The company specializes in oncolytic immunotherapies, with its lead candidate, cretostimogene grenadenorepvec, designed as a targeted, intravesical immunotherapy. Currently, CG Oncology is conducting multiple clinical trials, including two phase three trials aimed at high-risk patients with non-muscle invasive bladder cancer (NMIBC) who are unresponsive to BCG therapy, as well as an additional phase two study in combination with a checkpoint inhibitor. The company aims to provide effective bladder-sparing treatment options for patients while advancing the development of its proprietary therapies.

Poseida Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapeutics for patients with significant unmet medical needs. The company utilizes non-viral gene engineering technologies to create a pipeline of targeted therapies, including both autologous and allogeneic chimeric antigen receptor T cell (CAR-T) product candidates aimed at treating hematological malignancies and solid tumors. Additionally, Poseida is advancing gene therapies for rare and life-threatening conditions, such as Ornithine transcarbamylase deficiency, methylmalonic acidemia, and various genetic liver diseases. Founded in 2014, Poseida is committed to addressing critical health challenges through its focused research and development efforts.

Poseida Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapeutics for patients with significant unmet medical needs. The company utilizes non-viral gene engineering technologies to create a pipeline of targeted therapies, including both autologous and allogeneic chimeric antigen receptor T cell (CAR-T) product candidates aimed at treating hematological malignancies and solid tumors. Additionally, Poseida is advancing gene therapies for rare and life-threatening conditions, such as Ornithine transcarbamylase deficiency, methylmalonic acidemia, and various genetic liver diseases. Founded in 2014, Poseida is committed to addressing critical health challenges through its focused research and development efforts.

Poseida Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapeutics for patients with significant unmet medical needs. The company utilizes non-viral gene engineering technologies to create a pipeline of targeted therapies, including both autologous and allogeneic chimeric antigen receptor T cell (CAR-T) product candidates aimed at treating hematological malignancies and solid tumors. Additionally, Poseida is advancing gene therapies for rare and life-threatening conditions, such as Ornithine transcarbamylase deficiency, methylmalonic acidemia, and various genetic liver diseases. Founded in 2014, Poseida is committed to addressing critical health challenges through its focused research and development efforts.

Xenex is a company focused on reducing healthcare-associated infections (HAIs) through its advanced ultraviolet disinfection technology. Founded in 2009 and based in San Antonio, Texas, Xenex has developed a portable device that utilizes pulsed xenon UV light to eliminate harmful microorganisms in hospital environments. Since launching its disinfection system in June 2010, the company’s devices have been integrated into infection control protocols in nearly three hundred hospitals across the United States. By effectively reducing the bacterial load that contributes to HAIs, Xenex aims to enhance patient safety and safeguard healthcare staff, ultimately striving to save lives and alleviate suffering in healthcare settings.

Artizan Biosciences, Inc. is a biotechnology company based in New Haven, Connecticut, founded in 2016. The company focuses on developing small molecule drugs aimed at treating serious diseases linked to intestinal inflammation. Utilizing its proprietary IgA-SEQ technology platform, Artizan distinguishes disease-driving bacteria within the intestinal microbiota. This innovative approach enables the development of precision therapeutics designed to address unmet medical needs in various conditions, including digestive disorders, obesity, autoimmune diseases, and disorders affecting the skin, lungs, and central nervous system. Through its research, Artizan aims to provide new and potentially curative treatment options for patients suffering from these diverse health challenges.

Wren Therapeutics Limited is a biopharmaceutical company based in Cambridge, United Kingdom, that specializes in the development of small molecule therapeutics targeting protein misfolding diseases. Founded in 2016, the company focuses on conditions such as Alzheimer's and Parkinson's diseases, type 2 diabetes, and various rare forms of amyloidosis. Wren's proprietary technology platform is grounded in a deep understanding of the origins of these diseases, drawing on extensive scientific research conducted at the University of Cambridge and Lund University. Through this innovative platform, Wren aims to advance drug discovery and development for a range of serious neurological and rare disorders.

Cilatus BioPharma AG is a consulting firm based in Sarnen, Switzerland, specializing in technical operations for the biopharma industry. Established in 2014, the company provides comprehensive services in CMC (Chemistry, Manufacturing, and Controls) development, regulatory affairs, quality management, and engineering for biological products. Cilatus supports biopharma companies of various sizes by offering expertise in strategy development and execution, project management, and operational management throughout the drug development lifecycle, from pre-clinical stages to commercial manufacturing. Their services include the selection and management of contract development and manufacturing organizations, quality assurance and control, tech transfer management, and regulatory submissions. By leveraging a team of experienced consultants, Cilatus BioPharma aims to facilitate the successful development and commercialization of biopharmaceutical products.

Kymab Limited is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, focused on discovering and developing fully human monoclonal antibody therapeutics. The company utilizes its proprietary Kymouse platform, which is part of the broader IntelliSelect® integrated platforms, to target difficult and novel drug challenges in various therapeutic areas, including immuno-oncology and immune-mediated diseases. Kymab’s technology allows for the generation of a diverse range of human antibodies, enhancing the potential for novel therapies in treating conditions such as cancer and autoimmune disorders. The company has established strategic collaborations, including partnerships with Heptares Therapeutics and LifeArc, to further its research and development efforts. Founded in 2009, Kymab Limited operates as a subsidiary of Kymab Group Limited.

Poseida Therapeutics is a clinical-stage biopharmaceutical company based in San Diego, California, dedicated to developing innovative therapeutics for patients with significant unmet medical needs. The company utilizes non-viral gene engineering technologies to create a pipeline of targeted therapies, including both autologous and allogeneic chimeric antigen receptor T cell (CAR-T) product candidates aimed at treating hematological malignancies and solid tumors. Additionally, Poseida is advancing gene therapies for rare and life-threatening conditions, such as Ornithine transcarbamylase deficiency, methylmalonic acidemia, and various genetic liver diseases. Founded in 2014, Poseida is committed to addressing critical health challenges through its focused research and development efforts.

3D4Medical Limited is a technology company focused on developing medical, educational, and health and fitness applications for various platforms, including iOS, Android, and Windows. Founded in 2004 and based in Dublin, Ireland, the company creates a range of apps designed to aid professional reference, student learning, and patient education. Their notable products include Essential Anatomy 2, Essential Skeleton, and iMuscle, among others. 3D4Medical also specializes in producing high-quality 3D medical images and animations, which are utilized by major publications worldwide. The company's innovative platform covers various aspects of human anatomy, muscle movement, and interactive radiology, allowing users to explore anatomical details in a 3D environment. As of late 2019, 3D4Medical operates as a subsidiary of Elsevier B.V.

Altan Pharma is a specialty pharmaceutical company focused on developing, manufacturing, and marketing injectable medications for hospital use. The company offers a diverse range of products, including flexible plastic bags, liquid vials, lyophilized vials, and ampoules. Its portfolio includes drugs used in various therapeutic areas such as pain management, anesthesia, epilepsy, oncology, anti-infectives, cardiovascular health, and gynecology. By providing these essential injectable medicines, Altan Pharma serves the needs of hospitals and other healthcare segments, ensuring access to critical treatments for patients.

Melinta Therapeutics, Inc. is a commercial-stage pharmaceutical company based in Morristown, New Jersey, specializing in the discovery, development, and commercialization of anti-infective therapies for bacterial infections in North America. The company offers a range of antibiotics, including Baxdela, Vabomere, Orbactiv, and Minocin, targeting various serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSIs) and gram-negative infections. Melinta is actively advancing its investigational antibiotic, delafloxacin, which is currently in Phase 3 development for ABSSSIs. Additionally, the company is engaged in research to develop new classes of antibiotics aimed at combating drug-resistant pathogens, particularly the ESKAPE group responsible for many hospital-acquired infections. Through its innovative approaches, Melinta Therapeutics addresses the urgent need for new therapies against drug-resistant infections, a critical public health challenge today.

Kymab Limited is a clinical-stage biopharmaceutical company based in Cambridge, United Kingdom, focused on discovering and developing fully human monoclonal antibody therapeutics. The company utilizes its proprietary Kymouse platform, which is part of the broader IntelliSelect® integrated platforms, to target difficult and novel drug challenges in various therapeutic areas, including immuno-oncology and immune-mediated diseases. Kymab’s technology allows for the generation of a diverse range of human antibodies, enhancing the potential for novel therapies in treating conditions such as cancer and autoimmune disorders. The company has established strategic collaborations, including partnerships with Heptares Therapeutics and LifeArc, to further its research and development efforts. Founded in 2009, Kymab Limited operates as a subsidiary of Kymab Group Limited.

Novan, Inc. is a clinical development-stage biotechnology company headquartered in Morrisville, North Carolina, focused on creating nitric oxide-based therapies for dermatological and oncovirus-mediated diseases. The company is engaged in the development of several clinical-stage dermatology product candidates, including SB204, a topical treatment for acne vulgaris; SB206, an anti-viral gel for viral skin infections; SB208, a broad-spectrum anti-fungal gel for skin and nail infections; and SB414, a topical cream for inflammatory skin diseases. Additionally, Novan is developing SB207, another topical anti-viral product candidate. By utilizing a proprietary technology platform that encapsulates nitric oxide in nano-particles, Novan aims to deliver therapeutic agents precisely to targeted areas in the body. Established in 2006, the company collaborates with strategic partners to advance its innovative therapies addressing unmet medical needs.

Serenus Biotherapeutics is a privately held specialty biopharmaceutical company focused on late-stage drug development and commercialization. The company specializes in in-licensing and registering therapies that have been approved in the United States, Europe, and Japan, aiming to address unmet medical needs that are prevalent in the African market. Serenus Biotherapeutics is dedicated to producing biopharmaceutical products designed to treat critical diseases, providing physicians with effective options to improve patient outcomes in regions with significant healthcare challenges.